X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Roche is in the early stages of designing the Phase 2 clinical trial including RG6042, to explore different doses of tominersen in a younger adult patient population with less disease burden.
Lead Product(s): Tominersen
Therapeutic Area: Genetic Disease Product Name: RG6042
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2022
Details:
Tominersen, previously IONIS-HTTRx or RG6042, is an investigational antisense therapy designed to reduce the production of all forms of the huntingtin protein (HTT), including its mutated variant, mHTT.
Lead Product(s): Tominersen
Therapeutic Area: Genetic Disease Product Name: RG6042
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ionis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
GENERATION HD1 is evaluating the efficacy and safety of tominersen IONIS-HTTRx or RG6042 treatment administered once every two months over a period of 25 months, compared to placebo.
Lead Product(s): Tominersen
Therapeutic Area: Genetic Disease Product Name: IONIS-HTTRx
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
Lead Product(s): Tominersen
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2020
Details:
The company is running a clinical study in cooperation with Roche to deliver RG6042 to patients with Huntington's disease, as the first disease-modifying drug.
Lead Product(s): Tominersen
Therapeutic Area: Genetic Disease Product Name: RG6042
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
